Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06541639 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 31, 2028 to Mar 2028
    • Study completion date: Jun 30, 2028 to Dec 2028
    v3
  2. Phase: Early Phase 1 to Phase 1v2 Show 6 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2024 to Mar 4, 2025
    • Study sites: 0 to 2
    • Eligibility criteria shortened, about 602 words
    • Secondary endpoints revised (6)
    • Collaborators revised (2)
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment. The main questions to answer are: Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.
Trial Details
NCT Number NCT06541639
Lead Sponsor Peking University
Collaborators: Shanghai Cancer Centre, Everest Medicines (China) Co.,Ltd.
Conditions
(from sponsor)		 Advanced or Recurrent Solid Tumors
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov